

Supplementary Table V. Summary of meta-analysis between kinesin expression and overall survival in breast cancer patients

Study	Year	Kinesin family member	Data extraction	Test method	Overall hazard ratio (95% CI)
Li <i>et al</i> ⁴	2020	KIF4A	Dataset	SC	1.53 (1.1-2.13)
Alfarsi <i>et al</i> ⁶¹	2018	KIF18A	Dataset	SC	2.75 (1.89-4.01)
Ogden <i>et al</i> ⁶²	2017	KIFC1	Tissue	M	3.45 (1.40-20.80)
Gao <i>et al</i> ⁶⁴	2020	KIF15	Dataset	SC	1.5 (1.21-1.85)
Wang <i>et al</i> ⁶⁵	2013	KIF26B	Tissue	U	1.919 (1.198-3.067)
Hemida <i>et al</i> ⁶⁶	2024	KIF18A	Tissue	M	1.677 (0.139-20.211)
Jinna <i>et al</i> ⁵⁶	2023	KIFC1	Tissue	SC	1.65 (1.03-2.64)
Liu <i>et al</i> ³⁹	2023	KIF2C	Tissue	U	1.56 (1.08-2.26)
Rodrigues-Ferreira <i>et al</i> ⁵⁷	2023	KIF4A	Tissue	SC	1.97 (1.59-2.44)

95% CI, 95% confidence interval; SC, survival curve; M, multivariate; U, univariate